Compare CVS Health Corp (CVS) vs Kimberly Clark Corp (KMB) Price & Performance

CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.

CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.

Kimberly-Clark (KMB) trades at $98.02, up 1.6% on the day, showing modest recovery from recent weakness. The stock faces bearish technical signals with support at $96 and resistance at $98. Fundamentally, the company maintains strong profitability with 11.79% net margins and consistent dividend payments, though revenue declined to $16.45B in 2025. Recent executive transitions and the pending Kenvue acquisition create both uncertainty and strategic opportunity.

KMB offers a compelling dividend yield above 5% with 54 consecutive years of increases, but faces execution risks from the Kenvue integration. Analyst consensus targets $117.25 (19% upside) with mixed sentiment (32% buy, 58% hold). The stock presents value for income investors but requires careful monitoring of acquisition progress and cash flow sustainability.